Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling
Authors:
- 1 April 2015
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 5 (4) , 348-350
Abstract
Summary: Dual and triple combination therapies with RAF inhibitors plus other targeted agents have demonstrated promising clinical utility in BRAFV600-mutant solid tumors. However, despite vertical inhibition at multiple nodes on the MAPK signaling pathway, resistant tumors emerge. Ahronian and colleagues show that in BRAF-mutant colorectal cancer, resistance involves reactivation of RAS/RAF/MEK/ERK signaling and may be overcome by newly emerging ERK inhibitors. Cancer Discov; 5(4); 348–50. ©2015 AACR. See related article by Ahronian et al., p. 358Keywords
This publication has 9 references indexed in Scilit:
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway AlterationsCancer Discovery, 2015
- Novel therapeutic options for relapsed hairy cell leukemiaLeukemia & Lymphoma, 2015
- Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung CancerMolecular Cancer Therapeutics, 2015
- Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibNew England Journal of Medicine, 2015
- eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapiesNature, 2014
- VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).Journal of Clinical Oncology, 2014
- VE-BASKET, a first-in-kind, phase II, histology-independent “basket” study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).Journal of Clinical Oncology, 2014
- Tumor adaptation and resistance to RAF inhibitorsNature Medicine, 2013
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK InhibitorsCancer Discovery, 2013